COX-2: A target for colon cancer prevention

被引：256
|
作者：
Marnett, LJ
DuBois, RN
机构：
[1] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Cell Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2002年 / 42卷
关键词：
cyclooxygenase; prostaglandins; NSAIDs; cancer; prevention;
D O I：
10.1146/annurev.pharmtox.42.082301.164620
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence: is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.
引用
收藏
页码：55 / +
页数：26
相关论文
共 50 条
12345